Genomic and proteomic biomarker discovery in neurological disease

Biomarker Insights

Volumn 2008, Issue 3, 2008, Pages 73-86

  Robeson, Ri Lee H ^a   Siegel, Andrew M ^a   Dunckley, Travis ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

aCGH; Alzheimer's disease; Biomarker; Gene expression profiling; Genomics; Neurodegeneration; Neurological disease; Parkinson's disease; Proteomics; SNP

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; COMPARATIVE GENOMIC HYBRIDIZATION; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DISEASE PREDISPOSITION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME ANALYSIS; GENOMICS; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUNTINGTON CHOREA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PARKINSON DISEASE; PELIZAEUS MERZBACHER DISEASE; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 39549115229     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/bmi.s596     Document Type: Review

References (91)

1. Andrade, É,C., Krueger, D.D. and Naim, A,C. 2007. Recent advances in neuroproteomics. Curr. Opin. Mol. Ther., 9(3):270-81.
2. Andreasen, N., Minthon, L., Davidsson, P. et, al. 2001. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer's disease in clinical practice. Arch. Neurol., 58(3):373-9.
3. Arai, H., Ishiguro, K., Ohno, H. et al. 2000. CSF Phospohrylated tau protein and mild cognitive impairment: a prospective study. Exp. Neurol., 166(1):2001-3.
4. Ardlie, K.G., Kruglyak, L. and Seielstad, M. 2002. Patterns of linkage disequilibrium in the human genome. Nat. Rev. Genet., 3(4):299-309.
5. Banks, R.E., Dunn, M.J., Hochstrasser, D.F. et al. 2000. Proteomics: new perpective, new biomedical opportunities. Lancet, 356(9243),1749-56.
6. Barrett, M.T., Scheffer, A., Ben-Dor, A. et al. 2004. Comparative genomic hybridizatioh using. oligonucleotide microarrays and total genomic DNA. Proc. Natl. Acad. Sci. U.S.A., 101(51):17765-70.
7. Baum, A.E., Akula, N.; Cabanero, M. et al. 2007. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol. Psychiatry, May. 8; [Epub ahead of print].
8. Bejjani, B.A. and Shaffer, L.G. 2006. Application of array-based comparative genomic hybridization to clinical diagnostics. J. Mol. Diagn., 8(5):528-33.
9. Blennow, K. and Vanmechelen, E. 2003. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res. Bull, 61(3)235-42.
10. Bonaglia, M.C., Giorda, R., Tenconi, R. et al. 2005. A 2.3Mb duplication of chromosome 8q24.3 associated with severe mental retardation and epilepsy detected by siandard karyotype. Eur J. Hum. Genet., 13(5):586-91.
11. Borovecki, F., Lovrećic, L., Zhou, J. et al. 2005. Genome-wide expression profiling of human blood reveals biomarkers for Huntingtons disease. Proc. Natl. Acad. Sci. U.S.A., 102(31):11023-28.
12. Brys, M., Pirraglia, E., Rich, K. et al..2007. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol. Aging, [Epub ahead of print].
13. Buerger, K., Padberg, F., Nolde, T. et al. 1999. CSF tau protein shows a better discrimination in young old (<70 years) than in old old patients, with Alzheimer's disease compared with controls. Neurosci Lett, 277(1):21-4.
14. Buerger, K., Zinkowski, R., Teipel, J.S. et al. 2003. Differentiation between Geriatric Major Depression and Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am. J. Psychiatry, 160(2):376-9.
15. Burczynski, M.E., Oestreicher, J.L., Cabilly, M.L. et al. 2005. Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. Curr Mol. Med., 5(1):83-102.
16. Butterfield, D.A., Perluigi, M. and Sultana, R. 2006. Oxidative atress in Alzheimer's disease brain: New insights from redox proteomics. Eur. J. Pharmacol., 545(1):39-50.
17. Canales, R.D., Luo, Y., Willey, J.C. et al. 2006. Evatuation of DNA micro-array results with quantitative gene expression platforms. Nat. Biotechnol., 24(9):115-22.
18. Carlson, C.S., Eberle, M.A., Rieder, M.J. et al. 2003. Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat. Genet., 33(4):518-21.
19. Coon, K.D., Myers, A.J., Craig, D.W. et al. 2007. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J. Clin. Psychiatry, 68(4):613-18.
20. Craig, D.W. and Stephan, D.A. 2005. Applications of whole-genome high-density SNP genotyping. Expert Rev. Mol. Diagn., 5(2):159-170.
21. Dalrymple, A., Wild, E.J., Joubett, R. et al. 2007. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammoatory activation and biomarker candidates. J. Proteome Res., 6(7):2833-40.
22. DeRisi, J., Penland, L., Brown, P.O. et al. 1996. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet., 14(4):457-60.
23. Diniz, B.S., Pinto, J.A. Jr., and Forlenza, O.V. 2007. Do CSF total tau, phosphorylated tau and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J. Biol. Psychiatry, [Epub ahead of print].
24. Dunckley, T., Coon, K.D. and Stephan, D.A. 2005. Discovery and development of biomarkers of neurological disease. Drug Discov. Today, 10(5):326-34.
25. Dunckley, T., Liang, W.S. and Stephan, D.A. 2006a. Evolution of translational genomic research strategies. In Williams, CR. (ed) Trends in Genome Research. Nova Science Publishers, Inc., Hauppauge, NY., pp. 1-24.
26. Dunckley, T., Beach, T.G., Ramsey, K.E. et al. 2006b. Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiol. Aging, 27(10):1359-71.
27. Dunckley, T., Huentelman, M.J., Craig, D.W. et al. 2007. Whole-genome analaysis of sporadic amyotrophic lateral sclerosis. N. Engl. J. Med., 357(8):775-788.
28. Edelmann, L., Prosnitz, A., Pardo, S. et al. 2007. An atypical deletion of the Willimas-Beuren syndrome interval implicates genes associated with defective visuospatial processing and autism. J. Med. Genet., 44(2):136-43.
29. Ewers, M., Buerger, K., Teipel, S.J. et al. 2007. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology, 69(24):2205-12.
30. Fuchs, E. and Weber, K. 1994. Intermediate filaments: structure, dynamics, function, and disease. Annu. Rev. Biochem., 63:345-82.
31. Fung, H.C., Scholz, S., Matarin, M. et al. 2006. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol., 5(11):911-6.
32. Galasko, D., Chang, L., Motter, R. et al. 1998. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer's disease and relation to apolipoprotein E genotype. Arch. Neurol., 55(7):937-45.
33. Garbern, J., Gambi, F., Shy, M. and Kamholz, J. 1999. The molecular pathogenesis oi Pelizaeus-Merzbacher disease. Arch. Neurol., 56(10):1210-4.
34. Green, A.J., Harvey, R.J., Thompson, E.J. et al. 1999. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci. Lett., 259(2):133-5.
35. Gulesserian, T., Seidl, R., Hardmeirer, R. et al. 2001. Soperoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J. Investig Med., 49(1):41-6.
36. Hampel, H., Goernitz, A. and Buerger, K. 2003. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Aβ1-42 proteins to phosphorylated tau protein. Brain Res. Bull, 61(3):243-53.
37. Herukka, S.k., Helisalmi, S., Hallikainen, M. et al. 2007. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol. Aging, 28(10):1631-2.
38. Hollingshead, D., Lewis, D.A. and Mirnics, K. 2005. Platform influence on DNA microarray data in postmortem brain research. Neurobiol. Dis., 18(3):649-55.
39. Hulstaert, F., Blennow, A., Ivanoiu, A. et al. 1999. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology, 52(8):1555-62.
40. Inoue, K., Osaka, H., Sugiyama, N. et al. 1996. A duplicated PLP gene causing Pelizaeus-Merzbacher disease detected by comparative multiplex PCR. Am. J. Hum. Genet., 59(1):32-9.
41. Inoue, K., Kanai, M., Tanabe, Y. et al. 2001, Prenatal interphase FISH diagnosis of PLP1 duplication associated with Pelizaeus-Merzbacher disease. Prenat. Diagn., 21(13):1133-6.
42. Inoue, K. 2005. PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Neurogenetics, 6(1):1-16.
43. International Multiple Sclerosis Genetics Consortium, Hafler D.A., Compston, A., Sawcer, S. et al. 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med., 357(9):851-62.
44. Johnson, M.D., Floyd, J.L. and Caprioli, R.M. 2006. Proteomics in diagnostic neuropathology. J. Neuropathol. Exp. Neurol., 65(9):837-45.
45. Jones, S.E. and Jomary, C. 2002. Culsterin. Int. J. Biochem. Cell. Biol., 34(5):427-31.
46. Kalchman, M.A., Graham, R.K., Xia, G. et al. 1996. Huntingtin is ubiquitinated and interacts with specific ubiquitin-conjugating enzyme. J. Biol. Chem., 271(32):19585-94.
47. Kanemaru, K., Kameda, N. and Yamanouchi, H. 2000. Decreased CSF amyloid beta42 and normal ?u levels in dementia with Lewy bodies. Neurology, 54(9):1875-6.
48. Kinoshita, Y, Uo, T., Jayadev, S. et al. 2006. Potential applications and limitations of proteomics in the study of neurological disease. Arch. Neurol., 63(12):1692-6.
49. Kohnken, R., Buerger, K., Zinkowski, R. et al. 2000. Detection tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett., 287(3):187-90.
50. Kruglyak, L. and Nickerson, D.A. 2DO1. Variation is the spice of life. Nat. Genet., 27(3):234-236.
51. Lee, J.A., Cheung, S.W., Ward, P.A. et al. 2005. Prenatal diagnosis of LP1, copy number by array comparative genomic hybridizations. Prenat. Diagn., 25(13):1188-91.
52. Lee, J.H., Cheng, R., Schupf, N. et al. 2007. The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch. Neurol., 64(4):501-6.
53. Liao, L., Cheng, D., Wang, J. et al. 2004. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J. Biol. Chem., 279(35):37061-8.
54. Liedtke, W., Edelmann, W., Bieh, P.L., et al. 1996. GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron, 17(4):607-15.
55. MacDonald, T.J., Brown, K.M., LaFleur, B. et al. 2001. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat. Genet., 29(2): 143-52.
56. Magic, Z., Radulovic, S. and Brankovic-Magic M. 2007. cDNA microarrays: identification of gene signatures and their application in clinical practice. J. BUON., 12(Suppl)1:S39-44.
57. Maraganore, D.M., de Andrade, M., Lesnick, T.G. et al. 2005. High resolution whole-genome association study of Parkinson disease. Am. J. Hum. Genet., 77(5):685-93.
58. Matarin, M., Brown, W.M., Scholz, S. et al. 2000. A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol., 6(5):414-20.
59. Mi, R., Chen, W. and Höke, A. 2007. From the Cover: Pleiotrophin is a neurotrophic factor for spinal motor neurons. Proc. Nat. Acad. Sci., U.S.A., 104:4664-9.
60. Molina, L., Touchon, J., Herpe, M. et al. 1999. Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. Neuroreport, 10(17):3491-5.
61. Motter, R., Vigo-Pelfrey, C., Kholodenko, D. et al. 1995. Reduction of β-amyloidpeptide-42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol., 38(4):643-8.
62. Papapetropoulos, S., Shehadeh, L. and McCorquodale, D. 2007. Optimizing human post-mortem brain tissue gene expression profiling in Parkinson's disease and other neurodegenerative disorders: From target "fishing" to translational breakthroughs. J. Neurosci. Res., 85(14):3013-24.
63. Papasssotiropoulos, A., Fountoulakis, M., Dunckley, T. et al. 2006. Genetics, transcriptomics, and proteomics of Alzheimer's disease. J. Clin. Psychiatry, 67(4):652-70.
64. Parnetti, L., Lanari, A., Amici, S. et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Neurol. Sci., 22(1):77-8.
65. Puffenberger, E.G. Hu-Lince, D., Parod, J.M. et al. 2004. Mapping of sudden infant death with dysgenesis of the testes syndrome (SIDDT) by a SNP genome scan and identification of TSPYL loss of function. Proc. Natl. Acad. Sci. U.S.A., 101(32):11689-94.
66. Rebhan, M., Chalifa-Caspi, V., Prilusky, J. and Lancet D. 1998. GeneCards: a novel functional genomicscompendium with automated data mining and query reformulation support. Bioinformatics, 14(8):656-64.
67. Regis, S., Filocamo, M., Mazzotti, R. et al. 2001. Prenatal diagnosis of Pelizaeus-Merzbacher disease: detection of proteolipid protein gene duplication by quantitativefluorescent multiplex PCR. Prenat. Diagn., 21(8):668-71.
68. Reiman, E.M., Webster, J.A., Myers, A.J. et al. 2007. GAB.2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron, 54(5):713-20.
69. Riemenschneider, M., Buch, K., Schmolke, M. et al. 1996. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci. Lett, 212(3):209-11.
70. Rohlff, C. 2000. Proteomics in molecular medicine: applications in central nervous systems disorders. Electrophoresis, 21(6):1227-34.
71. Schena, M., Shalop, D., Davis, A.W. et al. 1995. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science, 270(5235):467-70.
72. Scherzer, C.R., Eklund, A.C., Morse, L.J. et al. 2007. Molecular markers of early Parkinoson's disease based on gene expression in blood. Proc. Natl. Acad. Sci. U.S.A., 104(3) 955-60.
73. Schymiek, J.C., Scholz, S.W., Fung, H.C. et al. 2007. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls first stage analysis and public release of data. Lancet Neurol., 6(4):322-8.
74. Shalon, D., Smith, S.J. and Brown, P.O. 1996. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome. Res., 6(7):639-45.
75. Sharp, F.R., Xu, H., Lit, L. et al. 2006. The Future of Genomic Profiling of Neurological Diseases Using Blood. Arch. Neurol., 63(11):1529-56.
76. Shi, L., MAQC, Consortium, Reid, L.H. et al. 2006. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol., 24(9):1151-61.
77. Singleton, A.B., Farrer, M., Johnson, J. et al. 2003. alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302(5646):841.
78. Shirahata, M., Iwao-Koizumi, K., Saito, S. et al. 2007. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin. Cancer Res., 13(24):7341-56.
79. Sjögren, M., Minthon, L., Davidsson, P. et al. 2000, CSF levels of tau, β-amyloid (1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural. Trans., 107(5):563-79.
80. Sjögren, M., Davidsson, P., Tullberg, M. et al. 2001. Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neruosurg. Psychiatry, 70(5):624-30.
81. Tang Y., Schapiro, M.B., Franz, D.N. et al. 2004. Blood expression profiles for tuberous sclerosis complex 2, neurofibromatosis type 1, and Down's syndrome. Ann. Neurol., 56(6):808-14.
82. Tang, Y., Gilbert, D.L., Glauser, T.A. et al. 2005. Blood gene expression profiling of neurological diseases: a pilot microarray study. Arch. Neurol., 62(2):210-5.
83. Tannu, N.S. and Hemby, S.E. 2006. Methods for proteomics in neuroscience. Prog. Brain Res., 158:41-82.
84. The GAIN. Collaborative Research Group, Manolio, T.A., Rodriguez, L.L. et al. 2007. New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat. Genet., 39(9):1045-1051.
85. Toruner, G.A., Streck, D. L., Schwalb, M.N. and Dermody, J.J. 2007. An oligonucleotide based array-CGH system for detection of genome wide copy number changes including subtelomeric regions for genetic evaluation of mental retardation. Am. J. Med. Genet. A., 143(8):824-9.
86. Ulmann, R., Turner, G., Kirchhoff, M. et al. 2007. Array CGH identifies reciprocal 16p13.1 duplications and deletions that predispose to autism and/or mental retardation. Hum. Mutat., 28(7):674-82.
87. van Es, M.A., Van Vught, P.W., Blauw, H.M. et al. 2007. ITPR.2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol., 6(10):869-77.
88. Vanmechelen, E., Vanderstichele, H., Davidsson, P. et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neruosci. Lett., 285(1):49-52.
89. Vigo-Pelfrey, C., Seubert, P., Barbour, R. et al. 1995. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology, 45:788-93.
90. Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 447(7145):661-78.
91. Woodward, K., Palmer, R., Rao, K. and Malcolm, S. 1999. Prenatal diagnosis by FISH in a family with Pelizaeus-Merzbacher disease caused by duplication of the PLP gene. Prenat. Diagn., 19(3):266-8.